PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChat
10 Visualizações
• 07/08/23
0
0
Embutir
administrator
Assinantes
UCLA oncologist Gottfried Konecny, MD, gives an overview of the PARP inhibitors olaparib, niraparib, and rucaparib, which have been approved for the treatment of ovarian cancers and how to proactively plan for and manage treatment-related toxicities. #UCLAMDChat
Mostre mais
Comentários do Facebook
SORT BY-
Melhores Comentários
-
Últimos Comentários